Xoma | XOMA - Beneficio Operativo





Beneficio Operativo Cambio Fecha
AbbVie USD 4.73B 1.08B 2026-03
Agenus USD 14.4M 19.26M 2025-12
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Ardelyx USD 5.1M 431K 2025-12
aTyr Pharma USD 24.47M 51.21M 2025-12
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Celldex Therapeutics USD -87.15M 13.54M 2025-12
Curis USD -7.88M 4.63M 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Emergent BioSolutions USD -218M 69.9M 2023-06
Incyte USD 324.17M 59.7M 2026-03
MacroGenics USD -12.1M 30.74M 2025-12
Novartis USD 4.24B 171M 2026-03
Novartis USD 4.06B 521M 2025-12
Pfizer USD 4.99B 340M 2026-03
Prothena USD -27.21M 12.55M 2025-12
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Xoma USD -15.64M 5.56M 2024-09